Articles tagged "FK506"

2019 American Transplant Congress
BK Virus Infection Disparity between Black and Other Races; Do Not Blame the Mycophenolic Acid
N. Raj¹, R. Spong¹, S. Jackson², V. Vakil¹, D. Keys¹, E. Finger³, S. Riad¹
¹Medicine, University of Minnesota, Minneapolis, MN, ²Complex Care Analytics, Fairview Health Services, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Disparities in kidney transplant outcomes between black recipients and others continue to exist. We sought to examine the impact of race and the differential…
2019 American Transplant Congress
FK506 Influence Glucose Metabolism by Short Chain Fatty Acid
W. Jiao¹, Z. Zhang¹, L. Liu², X. Hu¹
¹Urology, Capital Medical University Beijing Chaoyang Hospital, Beijing, China, ²GI Divison, West China Hospital, Beijing, China
*Purpose: FK506 is one of the most common immunosuppressant drugs in organ transplantation, which have been demonstrated to cause glucose metabolism disorder and alterd the…
2019 American Transplant Congress
Gut Microbiota May Affect a Variability of Tacrolimus Trough Levels in Kidney Transplant Recipients
J. Kim¹, H. Cho², J. Park³, M. Kwak⁴, B. Kim⁴, J. Lee⁵, D. Kim¹, B. Kim⁶, Y. Kim¹, H. Lee¹
¹Seoul National University Hospital, Seoul, Korea, Republic of, ²Chungbuk National University Hospital, Cheongju, Korea, Republic of, ³Kangwon National University Hospital, Chuncheon, Korea, Republic of, ⁴Chunlab Inc., Seoul, Korea, Republic of, ⁵Seoul National University Boramae Hospital, Seoul, Korea, Republic of, ⁶Hallym University, Chuncheon, Korea, Republic of
*Purpose: The gut microbiota alters expression of drug-metabolizing enzymes and transporters, and consequently affects therapeutic dose and response of medicines. We aimed to investigate the…
2019 American Transplant Congress
Not All Poor Metabolizers Are Clinically Equal: Evaluating Weight-Based Tacrolimus Outcomes in CYP3A Loss of Function Variants
A. Q. Maldonado, W. Irish, T. E. Asempa, J. Gooden, M. L. Davis, C. Haisch, H. Jones, D. Leeser, L. Rebellato
Vidant Medical Center - Transplant Services, Greenville, NC
*Purpose: CYP3A polymorphisms are an important pharmacotherapeutic consideration due to the extensive CYP metabolism of tacrolimus (TAC) and variable expression among different races. The CPIC…
2019 American Transplant Congress
mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis
V. N. Nguyen¹, R. Abagyan², S. Tsunoda²
¹Pharmacy, UC San Diego Health, San Diego, CA, ²Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA
*Purpose: Our study aimed to compare the adverse events (AEs) of tacrolimus to mammalian target of rapamycin (mTOR) inhibitors in solid organ transplant patients.*Methods: Our…
2019 American Transplant Congress
Increasing Time-in-Therapeutic Range of Tacrolimus is Associated with Superior Outcomes in Living Kidney Transplants
T. Lin, T. Song, S. Yin, Y. Jiang, Z. Huang, X. Wang, J. Liu, Z. Wang
Organ Transplantation Center, Urology Department, Urology Research Institute, WestChina Hospital, Sichuan University, Chengdu, China
*Purpose: Tacrolimus-based regimens remain the backbone of maintenance immunosuppressive therapy in kidney transplant, and therapeutic drug monitoring of tacrolimus is necessary due to a narrow…
2019 American Transplant Congress
CURATE.AI: Personalized Liver Transplant Tacrolimus Dosing
A. Zarrinpar¹, T. Kee², P. Wang³, J. Khong³, U. Kim¹, J. Chong², J. B. Jeong³, A. T. Truong², S. Tan², B. K. Betzler², W. Ng², C. Ho³, D. Ho²
¹Surgery, University of Florida, Gainesville, FL, ²National University of Singapore, Singapore, Singapore, ³UCLA, Los Angeles, CA
*Purpose: Transplant immunosuppressive regimens include multiple drugs with varying pharmacokinetics, metabolic pathways, and drug-drug interactions. This study aimed to use CURATE.AI, an artificial intelligence platform,…
2019 American Transplant Congress
LCP-Tacrolimus (LCPT; Envarsus XR) Dosing Considerations in De Novo Kidney Transplant Recipients
D. Cibrik¹, P. West-Thielke², S. J. Patel³, D. R. Stevens⁴, U. Meier-Kriesche⁴
¹University of Kansas Medical Center, Kansas City, KS, ²University of Illinois Hospital and Health Sciences System, Chicago, Chicago, IL, ³Veloxis Pharmaceuticals, Cary, NC, ⁴Veloxis Pharmaceuticals Inc., Cary, NC
*Purpose: Different initial dosing strategies were studied in Phase II/Phase III trials evaluating the pharmacokinetics, safety, and efficacy of LCPT in de novo kidney transplantation.…
2018 American Transplant Congress
Long-Term Effects of Ketoconazole in Rapid Tacrolimus Metabolizers Post-Renal Transplantation
J. Ching,¹ S. Anders,¹ M. Janusek,¹ L. Hutchinson,¹ A. Freeman,¹ U. Patel,¹ A. Mohammed,⁴ H. Bohorquez.^2,3
¹Department of Pharmacy, Ochsner Clinical Foundation, New Orleans, LA; ²Multi-Organ Transplant Institute, Ochsner Clinical Foundation, New Orleans, LA; ³The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA; ⁴Academic Center, Ochsner Clinical Foundation, New Orleans, LA.
Introduction: Genetic polymorphisms in cytochrome P-450 enzymes can cause variations in tacrolimus (tac) metabolism. Ketoconazole (keto), a potent CYP450 and P-glycoprotein inhibitor, can be used…
2018 American Transplant Congress
Time within Therapeutic Range: A Comparison of Three Tacrolimus Formulations in Renal Transplant Recipients
K. Khalil, P. West-Thielke, A. Lichvar, E. Benedetti, S. Patel.
University of Illinois Hospital & Health Sciences System, Chicago, IL.
Purpose: To compare three formulations of tacrolimus (TAC) and assess differences in time within therapeutic range (TTR) and variability in levels.Methods: Renal transplant recipients from…

« Previous Page
1
…
4
5
6
7
8
…
14
Next Page »